EXTRA CARDIAC SUPPORT DEVICE

Information

  • Research Project
  • 6015700
  • ApplicationId
    6015700
  • Core Project Number
    R43HL063553
  • Full Project Number
    1R43HL063553-01
  • Serial Number
    63553
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/27/1999 - 25 years ago
  • Project End Date
    8/31/2000 - 24 years ago
  • Program Officer Name
  • Budget Start Date
    9/27/1999 - 25 years ago
  • Budget End Date
    8/31/2000 - 24 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/26/1999 - 25 years ago
Organizations

EXTRA CARDIAC SUPPORT DEVICE

Heart disease is the leading cause of death in the U.S., killing approximately 750,000 annually. The proposed non-blood contacting, temporary ventricular support system is complementary, not competitive, with VADs and replacement hearts. Reduced risk of embolism and infection allows it to fill the gap between existent treatment options. The cuff's collapsible construction permits implantation without disruption of the sternum. Intended to be fully reversible, it offers a safe, cost-effective therapeutic option that can support a failing heart until recovery or other therapies are performed. The immediate goal is to demonstrate that a shape memory actuator based system can support a failing heart. The system is intended to be safer and more reliable than pneumatically driven devices. Direct conversion of electrical energy to mechanical work eliminates the risk of aneurization. The indwelling cuff follows heart motion without displacing other organs. Redundant actuator layers enhance reliability without increasing cuff volume. The elimination of bulky pneumatic drivelines reduces infection risk. Consisting of a small, quiet console linked to an indwelling cuff by a single l6F line, the system provides a therapeutic option in applications involving MI, congestive heart failure, emergency tsransport, post cardiotomy support, and bridge to transplantation. PROPOSED COMMERCIAL APPLICATIONS: In 1997 approximately 10% of the estimated $80 billion medical device market was due to sales of cardiovascular devices. The treatment of heart failure is the largest consumer of healthcare dollars in the U.S. There is a need for a less-invasive, easily reversible, but effective therapy, as a cost- effective method of supporting patients until either native heart function recovers or the patient's clinical condition is deemed appropriate for more long-term or permanent support.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    ABIOMED R AND D, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    DANVERS
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01923
  • Organization District
    UNITED STATES